Social Media Ideas for Rprx

Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Royalty Pharma: Strong Execution, Higher Guidance, And Room For A Re-Rating

RXO, Inc. (RXO) Presents at Morgan Stanley's 14th Annual Laguna Conference Transcript

<![CDATA[Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing ]]>

Royalty Pharma: The Quiet Compounder The Market Is Still Mispricing

Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania Transcript

Pfizer-backed Priovant wins FDA approval for lead asset

Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preli...

Rapid Micro Biosystems, Inc. (RPID) Presents at Small-Cap Virtual Conference - Slideshow

Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease - Slideshow

Arcturus sees positive results from mid-stage trial of RCT-810 in OTC deficiency

Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preli...

TRrexBio’s IPO Bags $116M to Bring the Immune System Back Into Balance

Eli Lilly-partnered TRexBio will apply the IPO proceeds toward clinical development of molecules designed to activate regulatory T cells to mediate immune responses and inflammatio...

Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference - Slideshow

Blenrep

Blenrep Anonymous (not verified) Tue, 09/08/2026 - 15:50 field_thread_url https://cafepharma.com/boards/threads/blenrep.714532/ board na...

TRex Bio prices $117M IPO to support immune drug work

Eli Lilly is the largest equity holder in TRex, which is developing drugs that treat immunological conditions by activating “Treg” cells.

Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan

<![CDATA[Pharmaceutical Executive Daily: Rona Therapeutics Enters Global License Agreement for ALK7-targeting RNAi Th...

Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment...

Praxis

Praxis Anonymous (not verified) Mon, 08/31/2026 - 12:44 field_thread_url https://cafepharma.com/boards/threads/praxis.717326/ board name...

<![CDATA[Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million ]]>

CareTria Launches RYALTRIS® Direct, Expanding Patient Access Through Pharmacy, Telesales, and Sampling Support

New offering creates a connected path from product sample to prescription fulfilment, helping simplify access to RYALTRIS® for providers and patients LAKEWOOD, N.J., Sept. 17, 202...

Eli Lilly-backed TRex Bio closes day flat after IPO

Ractigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mecha...

First clinical evidence demonstrating that a systemically delivered small activating RNA (saRNA) can safely upregulate an endogenous target protein in human skeletal muscle in a mo...